Skip to main content
. Author manuscript; available in PMC: 2020 Mar 31.
Published in final edited form as: Leuk Res. 2019 Aug 1;85:106197. doi: 10.1016/j.leukres.2019.106197

Fig. 1.

Fig. 1.

Study design.

Abbreviations: PAN, panobinostat; IDA, idarubicin; Ara-C, cytarabine; D, day; MWF, Monday Wednesday and Friday; MTD, maximum tolerated dose; R2PD, recommended dose for phase 2 studies; CR, complete remission; CRi, complete remission with incomplete blood count recovery.

Primary AML was defined as newly diagnosed disease according to World Health Organization criteria of with ≥ 20% of bone marrow blasts by bone marrow aspiration or biopsy and the patient had not been treated for AML.

Secondary AML was defined as treatment-related AML, or AML arising from previously diagnosed myelodysplasia (MDS) or other antecedent hematologic disorders (AHDs).